Dana-Farber Cancer Institute | Strategic Alliance Partners

Researchers are optimistic about epigenetic tools for studying the impact of environmental exposures on genes, but further investigations are needed before drawing conclusions on the causes of early-onset colorectal cancer.

Vinayak Venkataraman, MD, discusses how certain biological requirements for emerging cellular therapies could exacerbate racial disparities in sarcoma.

Dr Cooper discusses recent advances that have reshaped the treatment paradigm for small cell lung cancer, particularly in the relapsed setting.

Timothy N. Clinton, MD, discusses biologic and anatomical differences underlying sex and gender disparities in bladder cancer incidence.

Sara M. Tolaney, MD, MPH, discusses how the shifting understanding of HER2 expression in breast cancer may affect the management of this disease.

Peter Enzinger, MD, discusses diagnostic pathways, the role of surgery, and ongoing trials of interest in esophageal cancer in this clinician-focused FAQ.

Timothy N. Clinton, MD, discusses differences between genders in terms of bladder cancer presentation.

Sara M. Tolaney, MD, MPH, discusses how the early-stage HER2-positive breast cancer treatment paradigm is evolving with the emergence of new phase 3 data.

Sara M. Tolaney, MD, MPH, discusses how therapeutic strategies are evolving within the HER2-positive breast cancer treatment paradigm.

Dana-Farber Cancer Institute announced a gift to support cancer prevention and establish the Larry and Susan Marx Chair for Early Detection.

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

Drs Matulonis and Stover explore the biology and therapeutic relevance of the RAS/MAP kinase pathway in gynecologic cancers.

Vinayak Venkataraman, MD, spotlights a focus-group study identifying mobility, autonomy, and supportive care gaps in AYA patients with sarcoma.

Toni Choueiri, MD, of Dana-Farber Cancer Institute, was elected to The Association of American Physicians.

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial.

Peter C. Enzinger, MD, discusses the significance of Claudin 18.2 and HER2 as actionable biomarkers in gastroesophageal cancer.

Treatment with daraxonrasib led to PFS and OS benefits vs SOC cytotoxic chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

Researchers used a genome-wide CRISPR knockout screen to pinpoint genes that help human AML cells avoid being engulfed by macrophages.

Multicancer early detection testing has emerged as an exciting strategy to expand cancer screening.

Jennifer R. Brown, MD, PhD, discusses the design of the AMPLIFY trial and safety data for acalabrutinib plus venetoclax in chronic lymphocytic leukemia.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinib plus venetoclax for chronic lymphocytic leukemia and how it improves QOL.

Jennifer R. Brown, MD, PhD, discusses ongoing clinical trials that she has her eye out for in chronic lymphocytic leukemia.

Kathleen Burns, MD, PhD, of has been elected as Fellow of the American Association for the Advancement of Science.

The addition of palbociclib to maintenance HER2-directed and endocrine therapy improved PFS vs SOC therapy alone in HER2-positive advanced breast cancer.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinb and venetoclax for chronic lymphocytic leukemia and its effect on patient QOL.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may influence clinical practice in the near future.

Xiao Wei, MD, MAS, discusses the FDA approval of Pylarify TruVu for detecting PSMA-positive lesions in prostate cancer.